A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in human epidermal growth factor receptor 2 negative, hormone receptor-positive breast cancer patients with bone metastases

被引：0
|
作者：
Rugo, H. S.
Huang, L.
Petrenciuc, O.
Zaccarini, P.
Coleman, R. E.
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Bayer HealthCare, Whippany, NJ USA
[3] Bayer SpA, Milan, Italy
[4] Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-OT2-01-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-01-11
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
    Zhao, Hongmeng
    Li, Dan
    Li, Qian
    Zhang, Bin
    Xiao, Chunhua
    Zhao, Ying
    Ge, Jie
    Yu, Yue
    Jia, Yumian
    Guo, Xiaojing
    Cao, Xuchen
    Wang, Xin
    ONCOLOGIST, 2024, 29 (06): : e763 - e770
  • [22] Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
    Bachelot, Thomas
    Bourgier, Celine
    Cropet, Claire
    Ray-Coquard, Isabelle
    Ferrero, Jean-Marc
    Freyer, Gilles
    Abadie-Lacourtoisie, Sophie
    Eymard, Jean-Christophe
    Debled, Marc
    Spaeth, Dominique
    Legouffe, Eric
    Allouache, Djelila
    El Kouri, Claude
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) : 2718 - 2724
  • [23] XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
    Peter Schmid
    Javier Cortes
    Ana Joaquim
    Noelia Martínez Jañez
    Serafín Morales
    Tamara Díaz-Redondo
    Sibel Blau
    Patrick Neven
    Julie Lemieux
    José Ángel García-Sáenz
    Lowell Hart
    Tsvetan Biyukov
    Navid Baktash
    Dan Massey
    Howard A. Burris
    Hope S. Rugo
    Breast Cancer Research, 25
  • [24] XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
    Schmid, Peter
    Cortes, Javier
    Joaquim, Ana
    Janez, Noelia Martinez
    Morales, Serafin
    Diaz-Redondo, Tamara
    Blau, Sibel
    Neven, Patrick
    Lemieux, Julie
    Garcia-Saenz, Jose Angel
    Hart, Lowell
    Biyukov, Tsvetan
    Baktash, Navid
    Massey, Dan
    Burris, Howard A., III
    Rugo, Hope S.
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [25] Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer
    Mouabbi, Jason A.
    Osborne, C. Kent
    Schiff, Rachel
    Rimawi, Mothaffar F.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (02) : 189 - 201
  • [26] Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Burris, Howard A., III
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 201 - 213
  • [27] Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
    Rugo, Hope S.
    Bardia, Aditya
    Marme, Frederik
    Cortes, Javier
    Schmid, Peter
    Loirat, Delphine
    Tredan, Olivier
    Ciruelos, Eva
    Dalenc, Florence
    Pardo, Patricia Gomez
    Jhaveri, Komal L.
    Delaney, Rosemary
    Fu, Olivia
    Lin, Lanjia
    Verret, Wendy
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (29) : 3365 - +
  • [28] Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
    Tan, Aihua
    Nong, Li
    Wang, Hongxue
    Jia, Yuxian
    Zhong, Wuning
    Qin, Fanghui
    Wang, Han
    Tang, Jing
    Liu, Yan
    Lu, Yongkui
    CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [29] A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer
    Yardley, Denise A.
    Awada, Ahmad
    Cortes, Javier
    Burris, Howard A.
    Peterson, Amy C.
    Tudor, Iulia Cristina
    Stopatschinskaja, Shanna
    Steinberg, Joyce Leta
    Gianni, Luca
    Miller, Kathy D.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
    Smith, Matthew
    Parker, Chris
    Saad, Fred
    Miller, Kurt
    Tombal, Bertrand
    Ng, Quan Sing
    Boegemann, Martin
    Matveev, Vsevolod
    Piulats, Josep Maria
    Zucca, Luis Eduardo
    Karyakin, Oleg
    Kimura, Go
    Matsubara, Nobuaki
    Nahas, William Carlos
    Nole, Franco
    Rosenbaum, Eli
    Heidenreich, Axel
    Kakehi, Yoshiyuki
    Zhang, Amity
    Krissel, Heiko
    Teufel, Michael
    Shen, Junwu
    Wagner, Volker
    Higano, Celestia
    LANCET ONCOLOGY, 2019, 20 (03): : 408 - 419
12345